rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Tyson Foods, Inc.

TSN · NYSE

Consumer StaplesFood ProductsNot moving yet

TSN stood above a rising 150-day average in 23 of the last 52 weekly readings, and has been out of that trend for the last 20 weeks. It is 6.9% below that average now. Food Products: 18% of its 55 stocks in an uptrend (−7 points in four weeks); Consumer Staples: 24% (+1 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 20
Industry in uptrend
18% -7 in 4 wk
Insider buys, 12 months
$2.0M
Insider sales, 12 months
$6.2M
Officials’ trades on record
34

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

17 Apr – 16 Oct
10%22%35%Apr 26Jun 26Jul 26Sep 26Oct 26

Food Products: Few of its stocks are in an uptrend and the share has been slipping. Consumer Staples: A minority of its stocks are in an uptrend and the share has held steady.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$27.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

34 disclosed lines: House 18, Senate 7, executive 9; 13 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k26 Aug 2026filed 8 Oct 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$500k–$1M20 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k23 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$50k–$100k12 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$100k–$250k18 May 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$500k–$1M17 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$50k–$100k10 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k17 Mar 2026filed 14 May 2026
Val T. Hoyle House: U.S. House ClerkOR04soldspouse$1k–$15k23 Sep 2025filed 10 Oct 2025
Val T. Hoyle House: U.S. House ClerkOR04boughtspouse$1k–$15k29 Oct 2024filed 12 Sep 2025
Tommy Tuberville Senate: U.S. Senate eFDSenatorsold part ofjoint$1k–$15k7 Sep 2023filed 13 Oct 2023
Daniel S. Goldman House: U.S. House ClerkNY10sold$1k–$15k14 Jul 2023filed 13 Aug 2023

Insiders

Buy orders, 12 months1
Sale orders, 12 months2
Buyers · sellers1 · 2
WhoDidSharesTraded
Jeffrey K. SchomburgerPresident & CEO Electbought19,450at $51.504 Sep 2026filed 8 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

News

Everyone who traded it

Jeffrey K. Schomburger Company insiderPresident & CEO Elect · last 4 Sep 20262 · 0
Donald J. Trump Executive branchWhite House Office · last 26 Aug 20264 · 4
John H. Tyson Company insiderChairman of the Board · last 10 Jul 20260 · 13
Wes Morris Company insiderChief Operating Officer · last 10 Jul 20261 · 3
Devin Cole Company insiderChief Operating Officer · last 10 May 20260 · 0
Adam S. Deckinger Company insiderChief Legal & Admin Officer · last 10 Feb 20260 · 1
Jacqueline Hanson Company insiderChief People Officer · last 9 Feb 20260 · 0
John R. Tyson Company insiderDirector · last 7 Feb 20260 · 0
Barbara Tyson Company insiderDirector · last 6 Feb 20260 · 1
Cheryl Miller Company insiderDirector · last 6 Feb 20260 · 0
David J. Bronczek Company insiderDirector · last 6 Feb 20260 · 0
Katherine B. Quinn Company insiderDirector · last 6 Feb 20260 · 0

Same industry

UTZ Utz BrandsLeading+38%
MED MedifastIn trend+5%
LW Lamb Weston HoldingsJust started moving+16%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 27 Sep 20256.5%
Operating profit marginFY 2025 · to 27 Sep 20252.0%
Free cash flow marginFY 2025 · to 27 Sep 20252.2%
Return on capital employedFY 2025 · to 27 Sep 20253.6%
Cash conversionFY 2025 · to 27 Sep 2025455%
Debt to equityFY 2025 · to 27 Sep 20250.05×
Research spendFY 2025 · to 27 Sep 20250.2%
Revenue growthFY 2024 · to 28 Sep 20240.8%
Share count trendFY 2024 · to 28 Sep 202425.4%
Cash and equivalentsFY 2025 · to 27 Sep 2025$1.2B
Free cash flowFY 2025 · to 27 Sep 2025$1.2B

Analyst forecasts

No analyst forecasts yet.